HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer

Files in This Item:
AO51-7_867-872.pdf287.77 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer
Authors: Komatsu, Yoshito Browse this author →KAKEN DB
Yuki, Satoshi Browse this author
Sogabe, Susumu Browse this author
Fukushima, Hiraku Browse this author
Nakatsumi, Hiroshi Browse this author
Kobayashi, Yoshimitsu Browse this author
Iwanaga, Ichiro Browse this author
Nakamura, Michio Browse this author
Hatanaka, Kazuteru Browse this author
Miyagishima, Takuto Browse this author
Kudo, Mineo Browse this author
Munakata, Masaki Browse this author
Meguro, Takashi Browse this author
Tateyama, Miki Browse this author
Sakata, Yuh Browse this author
Issue Date: Sep-2012
Publisher: Informa Healthcare
Journal Title: Acta Oncologica
Volume: 51
Issue: 7
Start Page: 867
End Page: 872
Publisher DOI: 10.3109/0284186X.2012.682629
PMID: 22554343
Abstract: Background. In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI. We previously reported that IRIS is also effective as first-line treatment. Patients and Methods. Eligibility criteria included inoperable recurrent colorectal cancer with a confirmed diagnosis of adenocarcinoma, age ≥ 20 years, and no history of prior chemotherapy. S-1 (40-60 mg twice daily) was given orally on days 1 to 14, and irinotecan (100 mg/m2) and bevacizumab (5 mg/kg) were given intravenously on days 1 and 15 of a 28-day cycle. The primary endpoint was safety. The secondary endpoints included overall response (OR), progression-free survival (PFS), and overall survival (OS). Results. A total of 52 eligible patients were enrolled from October 2007 through March 2009. In safety analysis, the incidences of grade 3 or 4 adverse reactions were as follows: neutropenia, 27%; hypertension, 21%; and diarrhea, 17%. The overall response rate was 57.7%. Median progression-free survival was 16.7 months. Conclusion. IRIS plus bevacizumab is a well-tolerated, highly effective chemotherapeutic regimen that is easy to administer.
Type: article (author version)
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 小松 嘉人

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University